Focus: Accuray is a public oncology-focused medical device company specializing in directed radiation therapy platforms for cancer treatment. With $447M in FY2025 revenue, they operate as a mid-cap biotech with established commercial infrastructure.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Growing — net +9 jobs in 30d
20 jobs added vs 11 removed. Steady team buildout.
Accuray offers stability and technical depth for engineers in radiation oncology, but profitability challenges and modest hiring activity may limit career acceleration compared to higher-growth peers.
Lead program in Phase 3 with 7 active trials; represents core commercial validation of Accuray's radiation platform in oncology.
Help build intelligence for Accuray
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Accuray's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
+1 more
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now - MSN
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session Benzinga
8-K Filing: ACCURAY INC (ARAY) (CIK 0001138723) — EXHIBIT 99.1
EXHIBIT 99.1
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo